BioCentury
ARTICLE | Clinical News

Emricasan: Additional Phase II data

May 4, 2015 7:00 AM UTC

Additional data from a double-blind, U.S. Phase II trial in 38 patients with NAFLD, including patients with non-alcoholic steatohepatitis (NASH), showed that twice-daily 25 mg emricasan led to a media...